The GI Company: Specialists in GI Medicine
May 2008
The GI Company: Specialists in GI Medicine
In this interview, Fintan Walton talks to Nicholas Barker, President and CEO of The GI Company.
The GI Company: Specialists in GI Medicine
In this exclusive interview, Fintan Walton talks to Nicholas Barker, President and CEO of The GI Company. The interview commences with Nicholas discussing the academic origins of The GI Company, its technologies and its financial sources. Nicholas talks about the company’s lead programme, known as Intestinal Trefoil Factor (ITF) and explains how ITF promotes mucosal repair, thus giving the drug scope to treat several conditions. Nicholas mentions the benefits of applying a virtual company structure to The GI Company, and also covers the key attributes of a company wishing to partner the ITF programme. The interview is concluded with the prospects for ITF and its development for treating a range of indications.
Nicholas Barker
Dr Nicholas Barker, President and CEO of The GI Company, is a licensed UK pharmacist and holds a PhD in drug targeting and delivery. He has over 20 years of pharmaceutical product development experience, and has held senior executive roles in international business and management at a number of large pharmaceutical and smaller biotechnology companies. Dr Barker has significant experience in preclinical and clinical drug development, manufacture and industrialisation, as well as product registration and launch. During his industry career he has contributed to a number of successful product introductions including Nasacort Aq, Synercid, Taxotere, Plenaxis, Menorest and Dilacor XR.
The GI Company
The GI Company is a privately held, speciality biopharmaceutical company established to meet the clinical needs and commercial opportunities available in the field of gastrointestinal medicine.
The GI Company's strategy for success is to discover and develop products in key gastrointestinal indications with high medical need, identify and exploit ‘development-ready’ technologies for the near-term to reduce risks for shareholders and build a novel pipeline of products based on cutting-edge science in the gastrointestinal field, through leveraging resources from academic institutions and corporate partners.
Dr Nicholas Barker, President and CEO of The GI Company, is a licensed UK pharmacist and holds a PhD in drug targeting and delivery. He has over 20 years of pharmaceutical product development experience, and has held senior executive roles in international business and management at a number of large pharmaceutical and smaller biotechnology companies. Dr Barker has significant experience in preclinical and clinical drug development, manufacture and industrialisation, as well as product registration and launch. During his industry career he has contributed to a number of successful product introductions including Nasacort Aq, Synercid, Taxotere, Plenaxis, Menorest and Dilacor XR.
